Compare VTMX & WGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VTMX | WGS |
|---|---|---|
| Founded | 1998 | 2017 |
| Country | Mexico | United States |
| Employees | N/A | 1300 |
| Industry | | Retail: Computer Software & Peripheral Equipment |
| Sector | | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 2.6B |
| IPO Year | 2023 | N/A |
| Metric | VTMX | WGS |
|---|---|---|
| Price | $31.97 | $76.24 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | $30.50 | ★ $140.71 |
| AVG Volume (30 Days) | 80.9K | ★ 724.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 2.18% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $11.84 | $29.98 |
| Revenue Next Year | $11.55 | $24.85 |
| P/E Ratio | ★ $47.91 | $1,251.58 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $21.30 | $55.17 |
| 52 Week High | $37.41 | $170.87 |
| Indicator | VTMX | WGS |
|---|---|---|
| Relative Strength Index (RSI) | 39.74 | 39.00 |
| Support Level | $30.07 | $68.55 |
| Resistance Level | $32.01 | $76.21 |
| Average True Range (ATR) | 0.99 | 5.42 |
| MACD | -0.46 | 0.50 |
| Stochastic Oscillator | 8.66 | 28.33 |
Corporacion Inmobiliaria Vesta SAB de CV is an internally managed real estate company that owns, manages, develops, and leases industrial properties in Mexico. The Company's primary business is the acquisition, development, and management of industrial and distribution center real estate. The company designs and constructs park-to-suit projects across various industries; undertakes build-to-suit projects; and provides site selection, design and engineering, and sale and leaseback services. The primary source of revenue is the rental income received from customers under operating leases. It serves aerospace, automotive, food and beverage, logistics, medical devices, plastics, and other industries.
GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.